Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

Lignende værker

• ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
  af: Hata, Nobuhiro, et al.
  Udgivet: (2019)
• Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade
  af: Hata, Nobuhiro, et al.
  Udgivet: (2016)
• Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
  af: Funakoshi, Yusuke, et al.
  Udgivet: (2020)
• Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data
  af: Hatae, Ryusuke, et al.
  Udgivet: (2016)
• Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma)
  af: Funakoshi, Yusuke, et al.
  Udgivet: (2021)